Experienced in COVID-19

Henning Wege

Esslingen, BW, DE 
Experienced in COVID-19
Esslingen, BW, DE 
OverviewLocationsClinical Research

Overview

Henning Wege practices in Esslingen, Germany. Mr. Wege is rated as an Experienced expert by MediFind in the treatment of COVID-19. His top areas of expertise are Liver Cancer, Cholangiocarcinoma (Bile Duct Cancer), Cirrhosis, Hepato-Pancreato-Biliary Surgery, and Liver Transplant.

His clinical research consists of co-authoring 87 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of COVID-19.

Gender
Male

Locations

Esslingen, BW, Germany
Other Locations
Hamburg, HH, Germany
Eppendorf, HH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Doxorubicin Transdrug™ to Best Standard of Care in Patients With Advanced Hepatocellular Carcinoma. ReLive Study.
Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Doxorubicin Transdrug™ to Best Standard of Care in Patients With Advanced Hepatocellular Carcinoma. ReLive Study.
Enrollment Status: Completed
Publish Date: June 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
2017-01: Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
2017-01: Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: August 06, 2020
Intervention Type: Other
View 2 Less Clinical Trials

87 Total Publications

Tiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial.
Tiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial.
Journal: Advances in therapy
Published: July 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wege's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile